Dynamic CCN3 expression in the murine CNS does not confer essential roles in myelination or remyelination

Significance Remyelination is a natural regenerative process driven by oligodendrocytes that occurs following myelin damage. Understanding this process holds therapeutic value for demyelinating diseases such as multiple sclerosis, in which remyelination can fail. CCN3 is a matricellular protein previously reported to enhance oligodendrocyte progenitor differentiation and myelination in vitro and ex vivo. Here, we show that despite extensive and dynamic expression in the murine CNS in homeostasis and following toxin-induced myelin damage, CCN3 is not required for myelination or remyelination in vivo. Yet, the anatomically distinct expression pattern suggests unidentified roles of CCN3 in a range of neurological processes. This investigation provides a framework for future investigations of the expression and role of CCN proteins in the CNS. CCN3 is a matricellular protein that promotes oligodendrocyte progenitor cell differentiation and myelination in vitro and ex vivo. CCN3 is therefore a candidate of interest in central nervous system (CNS) myelination and remyelination, and we sought to investigate the expression and role of CCN3 during these processes. We found CCN3 to be expressed predominantly by neurons in distinct areas of the CNS, primarily the cerebral cortex, hippocampus, amygdala, suprachiasmatic nuclei, anterior olfactory nuclei, and spinal cord gray matter. CCN3 was transiently up-regulated following demyelination in the brain of cuprizone-fed mice and spinal cord lesions of mice injected with lysolecithin. However, CCN3−/− mice did not exhibit significantly different numbers of oligodendroglia or differentiated oligodendrocytes in the healthy or remyelinating CNS, compared to WT controls. These results suggest that despite robust and dynamic expression in the CNS, CCN3 is not required for efficient myelination or remyelination in the murine CNS in vivo.

[1]  E. Bruford,et al.  Correction to: The official unified nomenclature adopted by the HGNC calls for the use of the acronyms, CCN1–6, and discontinuation in the use of CYR61, CTGF, NOV and WISP 1–3 respectively , 2018, Journal of Cell Communication and Signaling.

[2]  F. Court,et al.  The inhibition of CTGF/CCN2 activity improves muscle and locomotor function in a murine ALS model , 2018, Human molecular genetics.

[3]  P. Bankhead,et al.  Characterization of a murine mixed neuron-glia model and cellular responses to regulatory T cell-derived factors , 2018, Molecular Brain.

[4]  Lars E. Borm,et al.  Molecular Architecture of the Mouse Nervous System , 2018, Cell.

[5]  T. Yamashita,et al.  B-1a lymphocytes promote oligodendrogenesis during brain development , 2018, Nature Neuroscience.

[6]  S. Hauser,et al.  Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial , 2017, The Lancet.

[7]  P. Hamilton,et al.  Regulatory T cells promote myelin regeneration in the Central Nervous System , 2017, Nature Neuroscience.

[8]  D. Geschwind,et al.  Neuronal CTGF/CCN2 negatively regulates myelination in a mouse model of tuberous sclerosis complex , 2017, The Journal of experimental medicine.

[9]  D. Lorrain,et al.  Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery , 2016, eLife.

[10]  W. Richardson,et al.  Rapid production of new oligodendrocytes is required in the earliest stages of motor skill learning , 2016, Nature Neuroscience.

[11]  R. Aebersold,et al.  On the Dependency of Cellular Protein Levels on mRNA Abundance , 2016, Cell.

[12]  M. Park,et al.  CCN3 overexpression inhibits growth of callosal projections via upregulation of RAB25. , 2015, Biochemical and biophysical research communications.

[13]  S. Linnarsson,et al.  Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq , 2015, Science.

[14]  A. Leask Yin and Yang revisited: CCN3 as an anti-fibrotic therapeutic? , 2015, Journal of Cell Communication and Signaling.

[15]  William D. Richardson,et al.  Motor skill learning requires active central myelination , 2014, Science.

[16]  W. Macklin,et al.  A New Model of Cuprizone-Mediated Demyelination/Remyelination , 2014, ASN neuro.

[17]  D. Song,et al.  Role of glycogenolysis in stimulation of ATP release from cultured mouse astrocytes by transmitters and high K+ concentrations , 2013, ASN neuro.

[18]  S. Barnett,et al.  Schwann Cells But Not Olfactory Ensheathing Cells Inhibit CNS Myelination via the Secretion of Connective Tissue Growth Factor , 2013, The Journal of Neuroscience.

[19]  Pierre J. Magistretti,et al.  Oligodendroglia metabolically support axons and contribute to neurodegeneration , 2012, Nature.

[20]  Jens Frahm,et al.  Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity , 2012, Nature.

[21]  Hui Zhang,et al.  Central nervous system remyelination in culture — A tool for multiple sclerosis research , 2011, Experimental Neurology.

[22]  M. Selbach,et al.  Global quantification of mammalian gene expression control , 2011, Nature.

[23]  W. Richardson,et al.  NG2 Glia Generate New Oligodendrocytes But Few Astrocytes in a Murine Experimental Autoimmune Encephalomyelitis Model of Demyelinating Disease , 2010, The Journal of Neuroscience.

[24]  L. Kular,et al.  NOV/CCN3 upregulates CCL2 and CXCL1 expression in astrocytes through β1 and β5 integrins , 2010, Glia.

[25]  Mingqiang Xie,et al.  Rostrocaudal Analysis of Corpus Callosum Demyelination and Axon Damage Across Disease Stages Refines Diffusion Tensor Imaging Correlations With Pathological Features , 2010, Journal of neuropathology and experimental neurology.

[26]  D. Rowitch,et al.  CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. , 2010, Cell stem cell.

[27]  H. Kawamura,et al.  CCN3 Inhibits Neointimal Hyperplasia Through Modulation of Smooth Muscle Cell Growth and Migration , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[28]  A. Nicot,et al.  NOV/CCN3 promotes maturation of cerebellar granule neuron precursors , 2010, Molecular and Cellular Neuroscience.

[29]  A. Leask Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2 , 2009, Journal of Cell Communication and Signaling.

[30]  Stephan Saalfeld,et al.  Globally optimal stitching of tiled 3D microscopic image acquisitions , 2009, Bioinform..

[31]  L. Lau,et al.  Functions and mechanisms of action of CCN matricellular proteins. , 2009, The international journal of biochemistry & cell biology.

[32]  M. Vingron,et al.  Paracrine control of oligodendrocyte differentiation by SRF-directed neuronal gene expression , 2009, Nature Neuroscience.

[33]  K. Lyons,et al.  Cooperative Regulation of Chondrocyte Differentiation by CCN2 and CCN3 Shown by a Comprehensive Analysis of the CCN Family Proteins in Cartilage , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  Allan R. Jones,et al.  Genome-wide atlas of gene expression in the adult mouse brain , 2007, Nature.

[35]  C. Naus,et al.  CCN3 (NOV) Interacts with Connexin43 in C6 Glioma Cells , 2004, Journal of Biological Chemistry.

[36]  E. Beyer Faculty Opinions recommendation of CCN3 (NOV) interacts with connexin43 in C6 glioma cells: possible mechanism of connexin-mediated growth suppression. , 2004 .

[37]  Richard Reynolds,et al.  NG2-expressing glial progenitor cells: an abundant and widespread population of cycling cells in the adult rat CNS , 2003, Molecular and Cellular Neuroscience.

[38]  Wolfgang Brück,et al.  Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. , 2002, Brain : a journal of neurology.

[39]  B. Perbal,et al.  The expression of ccn3 (nov) RNA and protein in the rat central nervous system is developmentally regulated , 2001, Molecular pathology : MP.

[40]  J. Kingdom,et al.  Expression of the human NOV gene in first trimester fetal tissues , 2001, Anatomy and Embryology.

[41]  B. Perbal NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues , 2001, Molecular pathology : MP.

[42]  E. Wilson,et al.  Binding properties and distribution of insulin-like growth factor binding protein-related protein 3 (IGFBP-rP3/NovH), an additional member of the IGFBP Superfamily. , 1999, The Journal of clinical endocrinology and metabolism.

[43]  K. Suzuki,et al.  Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice , 1998, Journal of Neuroimmunology.

[44]  P. Schofield,et al.  novH: differential expression in developing kidney and Wilm's tumors. , 1998, The American journal of pathology.

[45]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[46]  D. Foran,et al.  Myelin acquisition in the central nervous system of the mouse revealed by an MBP-Lac Z transgene , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[47]  V. Joliot,et al.  Proviral rearrangements and overexpression of a new cellular gene (nov) in myeloblastosis-associated virus type 1-induced nephroblastomas , 1992, Molecular and cellular biology.

[48]  W. Mcdonald,et al.  Central remyelination restores secure conduction , 1979, Nature.

[49]  S. Hall The effect of injections of lysophosphatidyl choline into white matter of the adult mouse spinal cord. , 1972, Journal of cell science.

[50]  Ichiji Tasaki,et al.  THE ELECTRO-SALTATORY TRANSMISSION OF THE NERVE IMPULSE AND THE EFFECT OF NARCOSIS UPON THE NERVE FIBER , 1939 .

[51]  E. Bruford,et al.  The official unified nomenclature adopted by the HGNC calls for the use of the acronyms, CCN1–6, and discontinuation in the use of CYR61, CTGF, NOV and WISP 1–3 respectively , 2018, Journal of Cell Communication and Signaling.

[52]  P. Chambon,et al.  Retinoid X receptor gamma signaling accelerates CNS remyelination , 2011, Nature Neuroscience.

[53]  P. Boor,et al.  CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation. , 2008, Kidney international.